World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
74
Citations
27458
World Ranking
2033
National Ranking
995

Overview

Richard Furie is affiliated with Northwell Health in the United States and has contributed extensively to medical research, notably in the fields of rheumatology, immunology, nephrology, and related subfields. Their scientific work primarily revolves around systemic lupus erythematosus (SLE) and its associated complications, particularly lupus nephritis.

The scientist's publications reflect a focus on clinical trials and treatment approaches for lupus nephritis and systemic lupus erythematosus. Notable recent papers include:

  • Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis (2020, New England Journal of Medicine)
  • B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial (2022, Annals of the Rheumatic Diseases)

Richard Furie frequently publishes in journals specializing in rheumatology and related diseases, with multiple contributions to the following venues:

  • Annals of the Rheumatic Diseases
  • Arthritis & Rheumatology
  • Lupus Science & Medicine
  • Abstracts
  • The Journal of Rheumatology

Their research collaborations include frequent co-authors such as Eric F. Morand, Kenneth Kalunian, Raj Tummala, Maria Dall'Era, and Ronald van Vollenhoven, illustrating a network of interdisciplinary partnerships in systemic lupus erythematosus research.

Richard Furie's main fields of study encompass:

  • Medicine

Within this broader area, they have specialized in several subfields, including:

  • Rheumatology
  • Radiology, Nuclear Medicine and Imaging
  • Immunology
  • Nephrology
  • Oncology

The specific topics addressed in their research highlight an emphasis on:

  • Systemic Lupus Erythematosus Research
  • Monoclonal and Polyclonal Antibodies Research
  • Renal Diseases and Glomerulopathies
  • Cytokine Signaling Pathways and Interactions
  • T-cell and B-cell Immunology
  • Liver Diseases and Immunity
  • Atherosclerosis and Cardiovascular Diseases

Best Publications

  • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

    Stanley B Cohen;Paul Emery;Maria W Greenwald;Maxime Dougados

  • A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

    Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera

  • Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study†

    Brad H. Rovin;Richard Furie;Kevin Latinis;R. John Looney

  • Trial of Anifrolumab in Active Systemic Lupus Erythematosus

    Eric F Morand;Richard Furie;Yoshiya Tanaka;Ian N Bruce

  • Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

    Richard Furie;Munther Khamashta;Joan T. Merrill;Victoria P. Werth

  • The immune cell landscape in kidneys of patients with lupus nephritis

    Arnon Arazi;Deepak A Rao;Celine C Berthier;Anne Davidson

  • A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

    Dimitrios T. Boumpas;Richard Furie;Susan Manzi;Gabor G. Illei

  • A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus

    Daniel J. Wallace;William Stohl;Richard A. Furie;Jeffrey R. Lisse

  • Novel paradigms in systemic lupus erythematosus

    Thomas Dörner;Richard Furie

  • Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

    Munther Khamashta;Joan T Merrill;Victoria P Werth;Victoria P Werth;Richard Furie

  • Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

    Susan Manzi;Jorge Sánchez-Guerrero;Joan T Merrill;Richard Furie

  • Novel Evidence-Based Systemic Lupus Erythematosus Responder Index

    Richard A. Furie;Michelle A. Petri;Daniel J. Wallace;Ellen M. Ginzler

  • Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

    Richard A Furie;Eric F Morand;Ian N Bruce;Susan Manzi

  • High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis

    R. Kokkola;E. Sundberg;A.-K. Ulfgren;K. Palmblad

  • B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

    Richard A Furie;Gustavo Aroca;Matthew D Cascino;Jay P Garg

  • Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month, Randomized, Double-Blind Study†

    Richard Furie;Kathy Nicholls;Tien-Tsai Cheng;Frederic Houssiau

  • Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

    Richard Furie;William Stohl;Ellen M Ginzler;Michael Becker

  • LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study.

    Donato Alarcón-Segovia;James A. Tumlin;Richard A. Furie;James D. McKay

  • Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study

    Annett M. Jacobi;Weiqing Huang;Tao Wang;William Freimuth

  • Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

    J T Merrill;R F van Vollenhoven;J P Buyon;R A Furie

  • Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus

    Richard Furie;Victoria P. Werth;Joseph F. Merola;Lauren Stevenson

  • Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis.

    Chunyu Liu;Franak Batliwalla;Wentian Li;Annette Lee

  • The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.

    Weiqing Huang;Jayashree Sinha;Jeffrey Newman;Bhoompally Reddy

  • Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

    Ellen M. Ginzler;Daniel J. Wallace;Joan T. Merrill;Richard A. Furie

  • Immunoglobulin heavy chain variable region gene replacement As a mechanism for receptor revision in rheumatoid arthritis synovial tissue B lymphocytes.

    Kenji Itoh;Eric Meffre;Emilia Albesiano;Andrew Farber

  • Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy.

    E. Keystone;G. R. Burmester;R. Furie;J. E. Loveless

Frequent Co-Authors

Nicholas Chiorazzi
Nicholas Chiorazzi Feinstein Institute for Medical Research
Jorge L. Benach
Jorge L. Benach Stony Brook University
Sheila A. Lukehart
Sheila A. Lukehart University of Washington
Donato Alarcón-Segovia
Donato Alarcón-Segovia Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Anne Davidson
Anne Davidson Feinstein Institute for Medical Research
Jane E. Salmon
Jane E. Salmon Hospital for Special Surgery
Allen C. Steere
Allen C. Steere Harvard University
Dimitrios T. Boumpas
Dimitrios T. Boumpas National and Kapodistrian University of Athens
Roy L. Silverstein
Roy L. Silverstein Medical College of Wisconsin
Andrew G. Huvos
Andrew G. Huvos Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open diverse career pathways. Nursing fields, for example, often intersect with immunological expertise in patient care and research. Prospective students might consider the best easiest LPN programs to get into as a starting point, offering accessible routes into nursing with foundational clinical skills.

Advancing further, the easiest online nurse practitioner programs provide flexible options for specialization, including immunology-related fields. These programs balance quality education with convenience, ideal for working professionals aiming to deepen their expertise.

Specialized roles such as psychiatric-mental health nurse practitioners benefit from targeted training. Programs recognized for excellent clinical experience, like the online PMHNP programs with clinical placement, ensure graduates are well-prepared to meet patient needs in mental health, an area linked closely to immunological factors.

Cost-effective education is essential for many students. The cheapest PMHNP certificate programs provide affordable pathways to certification, making advanced immunology-related healthcare roles more accessible without compromising critical training.

By exploring these options, students can find programs that align with their career goals and lifestyle, enhancing their impact in Immunology and related healthcare sectors.

Best Scientists Citing Richard Furie

Trending Scientists

Recently Published Articles